HSBC: Unilever's US Growth Decelerates as Health Brands' Expansion Normalizes

Deep News02-16 20:11

Analysts at HSBC stated that the exceptional growth momentum previously seen in Unilever's health brands, Liquid IV and Nutrafol, is now returning to normal levels. This development is expected to lead to a slowdown in the overall business growth of Unilever in the United States.

The analysts noted that although the consumer goods giant anticipates improved performance in the fourth quarter, ongoing competition in the health segment remains a concern.

They further commented, "This could deprive Unilever of a key factor that had previously enabled it to outperform the broader market." At the same time, market expectations are leaning toward an acceleration in growth within emerging markets by 2026. Shares of Unilever declined 0.1% to £54.27.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment